Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05449132 · ClinicalTrials.gov registry record · Phase 3
Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee
A Phase 3 study, sponsored by Grünenthal.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT05449132 is a Phase 3 study that has completed, run by Grünenthal. The registered enrollment target is 466 participants.
The verdict
NCT05449132, a Phase 3 study, has completed, sponsored by Grünenthal.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.
Interventions
- DRUG Placebo
- DRUG RTX-GRT7039
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05449132
The ClinicalTrials.gov registry entry for NCT05449132 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05449132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05449132 about?
NCT05449132 is a clinical study titled "Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee". A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.
What is the current status of trial NCT05449132?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2022-09-26. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT05449132?
The interventions under investigation include: Placebo (DRUG), RTX-GRT7039 (DRUG).
Who is sponsoring clinical trial NCT05449132?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.